Slide 1: Q4 & Full Year 2025 Financial Results
1NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Q4 & Full Year 2025 Financial Results As of December 31, 2025, reported on March 12, 2026
Slide 2: Forward-looking statements
2NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future finan
Slide 3: Sanjiv Razdan, CEO, President and Director
3NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Sanjiv Razdan CEO, President and Director
Slide 4: Joint 2.0: first phase of our transformation journey
4NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Joint 2.0 the first phase of our transformation journey to reignite growth and improve profitability ✓ Significantly strengthened management team ✓ Achieved substantial progress with refranchising efforts ✓ Strengthened marketing activiti
Slide 5: Q4 2025 highlights
5NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | +3% Revenue From Continuing Operations Q4 2025 vs Q4 2024 +8% Consolidated Adjusted EBITDA Q4 2025 vs Q4 2024 1.1 M Shares Repurchased In Q4 2025 for total consideration of $9M +3.1 Revenue From Continuing Operations Q4 2025 vs Q4 2024 +7
Slide 6: Refranchising Company-Owned Clinics
6NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Refranchising Company-Owned Clinics • Signed Asset Purchase Agreement for the sale of 22 corporate-owned or managed clinics in Q4 2025 • Letter of Intent for sale of five additional corporate-owned or managed clinics in Q1 2026 • 48 remai
Slide 7: Driving Stronger New Patient Acquisition
7NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Driving Stronger New Patient Acquisition Shift from broad wellness-focused communications to a message centered on chiropractic care for pain relief • Increased National Marketing: growing awareness, began high- impact media program in No
Slide 8: Sales Driving Initiatives
8NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Sales Driving Initiatives • Continuing to test enhanced pricing structure in approximately 300 clinics • Expect comp sales trends will improve during the course of the year • Evaluating additional offerings to more closely match evolving
Slide 9: Elevating The Patient Experience
9NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Elevating The Patient Experience • Launched mobile app in July 2025 • Continuing to introduce new feature updates • 23,000+ patients shared app feedback • Average rating of 4.9 / 5.0 • 75% of patients waited less than 5 minutes to see a d
Slide 10: Scott Bowman, Chief Financial Officer
10NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Scott Bowman Chief Financial Officer
Slide 11: Operating Metrics
11NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | • $3.6M Q4 2025 consolidated Adjusted EBITDA +7.8% vs Q4 2024 • $140M Q4 2025 system-wide sales1 (3.9)% vs Q4 2024 • (3.8)% Q4 2025 comp sales2 vs Q4 2024 1 System-wide sales include revenues at all clinics, whether operated or managed b
Slide 12: Clinic Portfolio
12NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | 12 26 82 175 242 265 309 352 394 453 515 610 712 800 842 885 4 47 61 47 48 60 64 96 126 135 125 75 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TOTAL CLINICS OPEN at year-end Franchised Company-owned or
Slide 13: Three Months Ended December 31, 2025
13NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Three Months Ended December 31, 2025 $ in Millions 1 3 months ended 12/31/25 3 months ended 12/31/24 Difference Revenue $15.2 $14.7 +$0.5 Cost of revenues $2.8 $3.2 ($0.4) Selling and marketing $3.5 $2.8 +$0.7 Depreciation and amortizati
Slide 14: Year-Ended December 31, 2025
14NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Year-Ended December 31, 2025 $ in Millions 1 12 months ended 12/31/25 12 months ended 12/31/24 Difference Revenue $54.9 $52.2 +$2.7 Cost of revenues $11.2 $11.5 ($0.3) Selling and marketing $13.3 $11.0 +$2.3 Depreciation and amortization
Slide 15: Strengthening Balance Sheet
15NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Strengthening Balance Sheet $ in Millions 12/31/25 12/31/24 Unrestricted cash $23.6 $25.1 Restricted cash $0.7 $0.9 Borrowings on $20 Million JP Morgan Chase LOC $0.0 $0.0 Stock repurchase plan • Repurchased 1.1M shares for $9.0M during
Slide 16: 2026 Guidance Metrics
16NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | 2026 Guidance Metrics 2026 Guidance 2025 Low High Actual System-wide Sales 1 ($ in Millions) $519 $552 $532.4 Comp Sales 2 (%) (3)% 3% (0.4)% Consolidated Adjusted EBITDA ($ in Millions) $12.5 $13.5 $13.0 New Franchised Clinic Openings (
Slide 17: Revenue growth and royalty stream
17NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Revenue Growth Comp Growth New Clinic Growth Clinic Sales Royalty Stream 7.0% Marketing Fees 2.0% Technology Fees 1.5% Franchise Fees 0.5% System Wide Sales Revenue ~11.0% of Sales
Slide 18: Driving Higher Profitability
18NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Driving Higher Profitability ~10% - 12% of System Sales ~83% - 85% of Revenue Asset Capex ~3% of Revenue Free Ca ~60% - 70% FCF Conversion* ~40% - 42% of Revenue Royalties & Fees Gross Margin G&A Expense Capital Spending Free Cash Flow *
Slide 19: Capital Allocation Priorities
19NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Capital Allocation Priorities Investing In Growth Initiatives Buy Back RD Territories Share Repurchases
Slide 20: Sanjiv Razdan, CEO, President and Director
20NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Sanjiv Razdan CEO, President and Director
Slide 21: Establishing a Foundation for Sustainable Growth
21NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Establishing a Foundation for Sustainable Growth ✓ Improving financial position of franchisees and stockholders ✓ On track to become a pure-play franchisor ✓ Creating operating leverage ✓ Commitment to responsible capital allocation ✓ Pr
Slide 22: Performance Metrics and Non-GAAP Measures
22NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Performance Metrics and Non-GAAP Measures This presentation includes commonly discussed performance metrics. System-wide sales include revenues at all clinics, whether operated by the company or by franchisees. While franchised sales are
Slide 23: Quarterly GAAP – Non-GAAP Reconciliation
23NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Quarterly GAAP – Non-GAAP Reconciliation Three Months Ended December 31, 2025 2024 from Continuing Operations from Discontinued Operations Net Operations from Continuing Operations from Discontinued Operations Net Operations Non-GAAP Fin
Slide 24: Annual GAAP – Non-GAAP Reconciliation
24NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Annual GAAP – Non-GAAP Reconciliation Year Ended December 31, 2025 2024 from Continuing Operations from Discontinued Operations Net Operations from Continuing Operations from Discontinued Operations Net Operations Non-GAAP Financial Data
Slide 25: Contact
25NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Scott Bowman, CFO scott.bowman@thejoint.com The Joint Corp. 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960 Sanjiv Razdan, President & CEO sanjiv.razdan@thejoint.com The Joint Corp. 16767 N. Perimeter Dr., Suite